; 10-yrs OS: 45.9%); Poor (N = 13, male/female: 9/4; grading: 1-2/3: 6/7; median F.U.: 10.8; median CSS and OS 7.0 [95% CI 2-12]; 1-yr CSS/OS: 7.7%). A significant difference between Good and Poor patients was found for median age ( p = 0.021), resected nodes ( p = 0.018), and positive node-ratio ( p<0.0001). Seventeen (Good/Poor: 14/3), 11 (Good/Poor: 5/6) and 6 (Good/Poor: 2/4) RGC contained multiple, single or none gene alteration, respectively. The most frequently mutated genes (>3) follows: Conclusions: These exploratory findings suggest that NGS technologies with formalin-fixed and paraffin embedded tissues may potentially help to drive future customized therapies for RGC, and deserve to be prospectively tested together with clinical parameters in the context of larger samples. Disclosure: All authors have declared no conflicts of interest.
